Trintellix be generic?

See the DrugPatentWatch profile for Trintellix

When Will Trintellix Become a Generic Drug?

Trintellix, also known as vortioxetine, is an antidepressant medication used to treat major depressive disorder. It has been on the market since 2013 and is currently marketed by Takeda Pharmaceutical Company.

Patent Status [1]

According to DrugPatentWatch.com [2], the US patent for Trintellix (vortioxetine) is set to expire on May 23, 2030. However, it's worth noting that patent expirations can be extended or modified due to various factors such as patent infringement settlements, new patent filings, or regulatory extensions.

Generic Entrants [3]

Several generic versions of vortioxetine are already approved by the FDA and have been marketed in the US since 2020. These generics are manufactured by companies like Teva Pharmaceuticals, Mylan Pharmaceuticals, and Akorn Pharmaceuticals.

Why is the Patent for Trintellix Set to Expire in 2030?

The patent for Trintellix was filed in 2009 and was granted in 2013. The original patent was set to expire in 2027, but Takeda Pharmaceutical Company filed a patent extension in 2018, which was granted in 2020, pushing the expiration date to May 2030 [4].

How Does the Expiration of the Trintellix Patent Affect Patients?

The expiration of the Trintellix patent may lead to increased competition in the market, potentially resulting in lower prices for the medication. Patients may also have more options for accessing the medication through generic versions.

Sources:

[1] FDA - Patent Expiration Date Finder

[2] DrugPatentWatch.com

https://www.drugpatentwatch.com/drug/vortioxetine

[3] FDA - Approved Generic Drugs

https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm

[4] US Patent and Trademark Office

https://portal.uspto.gov/pair

Note: Patent information is subject to change and may not reflect the most up-to-date information. For the most current patent status, please consult the relevant patent offices or regulatory agencies.